Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
June 5th, 2020
6.9K views
This procedure was established to be used for developing advanced 3D hepatic cultures in vitro, which can provide a more physiologically relevant assessment of the genotoxic hazards associated with nanomaterial exposures over both an acute or long-term, repeated dose regimes.
Overview
This study presents a 3D Hep G2 spheroid model for in vitro testing of genotoxicity related to nanomaterial exposure. The model aims to reduce animal testing by providing a reliable assessment of DNA damage over extended periods.
Key Study Components
Area of Science
- Neuroscience
- Biotechnology
- Toxicology
Background
- The Hep G2 spheroid model mimics liver functionality and viability.
- It supports long-term culture and assessment of biochemical endpoints.
- Genotoxicity testing is crucial for evaluating nanomaterial safety.
- Reducing reliance on animal models is a significant ethical consideration.
Purpose of Study
- To develop a 3D hepatic culture system for assessing genotoxic hazards.
- To evaluate the effects of nanomaterials on DNA integrity.
- To establish a reliable in vitro model for long-term exposure studies.
Methods Used
- Seeding Hep G2 cells into a 96-well plate to form spheroids.
- Incubation of spheroids under controlled conditions.
- Exposure to engineered nanomaterials (ENMs) for genotoxicity assessment.
- Micronucleus assay to evaluate DNA damage.
Main Results
- Spheroids maintained viability and functionality for 14 days.
- Micronucleus assay indicated genotoxicity after acute ENM exposure.
- Long-term exposure showed varied genotoxic responses.
- Biochemical endpoints were successfully assessed from harvested spheroids.
Conclusions
- The 3D Hep G2 spheroid model is effective for genotoxicity testing.
- This model can minimize the need for animal testing in safety assessments.
- Further studies are needed to explore the implications of ENM exposure.
Frequently Asked Questions
What is the significance of using a 3D Hep G2 model?
The 3D Hep G2 model provides a more physiologically relevant system for assessing liver-related toxicological effects.
How long can the spheroids remain viable?
The spheroids can remain viable and functional for up to 14 days.
What types of endpoints can be assessed using this model?
Endpoints include cell viability, liver function assays, and genotoxicity assessments.
What are engineered nanomaterials (ENMs)?
ENMs are materials engineered at the nanoscale, which can have unique properties and potential toxicological effects.
What is the micronucleus assay?
The micronucleus assay is a test used to evaluate DNA damage by measuring the presence of micronuclei in cells.
Why is reducing animal testing important?
Reducing animal testing is crucial for ethical reasons and to comply with regulatory standards for humane treatment of animals.
Executive Industry Relevance
Advanced 3D liver models address the critical need for predictive in vitro systems to assess genotoxicity following long-term nanomaterial exposure, reducing reliance on animal testing. The HepG2 spheroid model supports extended culture up to 14 days, enabling repeated exposure regimes and evaluation of DNA damage via the micronucleus assay. This approach enhances mechanistic de-risking in early discovery by providing physiologically relevant data on hepatic metabolic activity and toxicological endpoints.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses related to nanomaterial-induced genotoxicity in a liver-relevant context.
- Operational Value: Supports biological de-risking through sustained viability and proliferative capacity over 14 days.
- Predictive Value: Enhances confidence in target validation by correlating nanomaterial exposure with fixed DNA damage assessment.
Screening & Assay Development
- Scientific Value: Prepares validated biological systems for downstream genotoxicity screening using the micronucleus assay.
- Operational Value: Ensures assay standardization and reproducibility through consistent spheroid formation (≤500 μm diameter).
- Scalability: Facilitates platform reuse for acute (24 h) and long-term (120 h) exposure regimes across multiple engineered nanomaterials.
Translational & Preclinical Research
- Translational Continuity: Maintains liver-like functionality (albumin, urea production) to bridge in vitro findings to in vivo relevance.
- Risk-Adjusted Advancement: Enables evaluation of a range of toxicological endpoints (cytotoxicity, inflammation, gene expression) to inform go/no-go decisions.
- Mechanistic De-risking: Clarifies dose- and time-dependent genotypic responses following nanomaterial exposure.
Pipeline & Workflow Integration
The 3D HepG2 spheroid model integrates into the discovery continuum from early target validation through preclinical screening, supporting hazard assessment workflows for nanomaterials and chemicals.
- Discovery Biology: Supports hypothesis testing on nanomaterial-induced DNA damage via micronucleus readouts.
- Screening: Delivers quantitative, reproducible outputs for genotoxicity and biochemical endpoints after exposure.
- Analytics: Enables comparison of acute versus long-term exposure effects on DNA integrity and liver function.
- Translational Research: Connects in vitro findings to preclinical continuity through sustained metabolic activity.
- Enterprise Reuse: Provides a scalable, cost-effective system for routine genotoxicity testing in contract research settings.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in genotoxicity assessment, reduction of mechanistic ambiguity in nanomaterial safety profiling.
- Operational Value: Standardization, reproducibility, and extended culture capacity (≤14 days) for repeated exposure studies.
- Strategic Value: Better go/no-go decisions, capital efficiency, and reduced late-stage biological risk in nanomaterial development.
- Portfolio Impact: Risk-adjusted prioritization based on genotoxicity and liver function data across exposure durations.
Implementation Considerations
- Requires expertise in 3D cell culture, spheroid formation, and micronucleus assay execution.
- Dependent on instrumentation for centrifugation, cytocentrifugation, and controlled incubation (37°C, 5% CO₂).
- Necessitates cross-team standardization of spheroid quality control (90–95% viability benchmark).
- Adaptation considerations include varying nanomaterial properties and exposure media compatibility.
- Practical limitations include the need for careful media handling during spheroid transfer and agarose embedding steps.
Biopharma FAQs
Why does micronucleus assay matter for target validation?
The micronucleus assay detects fixed DNA damage following nanomaterial exposure, providing a genotoxicity endpoint that supports therapeutic hypothesis interrogation in liver-relevant models.
How does independent variable isolation fit the discovery pipeline?
Isolating engineered nanomaterial concentration and exposure duration as independent variables enables clear assessment of dose- and time-dependent genotoxic responses in the 3D HepG2 model.
What quantitative dependent variable measurements enable predictive confidence?
Quantitative measurements of micronuclei frequency, albumin secretion, and urea production per spheroid provide measurable endpoints for comparing nanomaterial effects across exposure regimes.
Why do replication requirements matter for cross-functional collaboration?
Replication requirements ensure that 90–95% of spheroids form correctly and remain viable, supporting standardized data generation across teams and laboratories.
What statistical analysis capabilities are required before implementation?
Statistical analysis of micronucleus assay results and biochemical endpoints (e.g., liver function markers) is required to evaluate significance of genotoxic responses following acute and long-term nanomaterial exposure.
